Extension Study for the Port Delivery System With Ranibizumab (Portal)

Inclusion Criteria:

- Previous enrollment in and completion of Study GX28228 or Study GR40548, without early
treatment or study discontinuation in either study

- Ability and willingness to undertake all scheduled visits and assessments

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive measures

Exclusion Criteria:

- Pregnant or breastfeeding, or intending to become pregnant during the treatment period
and for at least 28 days after the last intravitreal injection of ranibizumab or 1
year after the last Implant refill of ranibizumab

- History of other ocular diseases that give reasonable suspicion of a disease or
condition that contraindicates the use of ranibizumab, that might affect
interpretation of the results of the study or that renders the participant at high
risk for treatment complications

- History of other diseases, metabolic dysfunction, or clinical laboratory finding
giving reasonable suspicion of a disease or condition that contraindicates the use of
ranibizumab or placement of the Implant and that might affect interpretation of the
results of the study or that renders the participant at high risk of treatment
complications

- Requirement for continuous use of any medications or treatments indicated in the
"Prohibited Therapy"